A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2019
Price : $35 *
At a glance
- Drugs TD 8954 (Primary)
- Indications Diabetic gastroparesis; Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 02 Jul 2018 Status changed from recruiting to completed.
- 18 May 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2018 New trial record